What diseases does Pralsetinib treat
Pralsetinib is an anti-tumor drug targeting RET gene mutations, mainly used to treat RET fusion positive non-small cell lung cancer and thyroid cancer, providing precise treatment options for patients with specific gene mutations.
1. Non small cell lung cancer
(1) Indications: Treatment for adult patients with metastatic RET fusion positive non-small cell lung cancer, especially for cases of traditional treatment failure.
(2) Clinical value: Designated by the FDA as an orphan drug for the treatment of JAK1/2 positive or TRKC positive non-small cell lung cancer, filling the gap in targeted therapy.
2. Thyroid cancer
(1) Target audience: Late stage or metastatic RET fusion positive thyroid cancer patients aged 12 years and above, as well as children.
(2) Treatment characteristics: Especially suitable for refractory cases caused by radioactive iodine, and has been granted orphan drug status by the FDA.
3. Other solid tumors
(1) Extended application: It also shows therapeutic potential for other solid tumors carrying RET gene mutations, such as medullary thyroid carcinoma.
(2) Medication restriction: RET mutation status must be confirmed through genetic testing before use.
Disclaimer：《What diseases does Pralsetinib treat》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！